EDX Medical confirms date for 2025 Annual General Meeting

EDX Medical

EDX Medical Group Plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced that its annual general meeting (AGM) will be held at the Marcus Beck Library, 3rd Floor, Royal School of Medicine, 1 Wimpole Street, Westminster, London, W1G 0AE on 29 September 2025 at 2:00 p.m.

The annual report and financial statements for the year ended 31 March 2025, Notice of AGM and Form of Proxy will be posted today, 1 September 2025, to eligible shareholders. Electronic copies will be shortly available on the Company’s website at: https://edxmedical.co.uk/documents/

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

EDX Medical confirms date for 2025 Annual General Meeting

EDX Medical will hold its AGM on 29 September 2025 at 2:00 p.m. at the Marcus Beck Library, Royal School of Medicine, London. The meeting will cover standard business matters and provide shareholders with an update on company progress.

EDX Medical reports 2025 results and advances in cancer diagnostics

EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust.

EDX Medical Group to complete the development of new pneumonia test

EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients. 

EDX Medical and Spire Healthcare sign MOU for diagnostic partnership

EDX Medical Group has partnered with Spire Healthcare to enhance digital diagnostics for cancer and other diseases, promising innovative patient care and improved outcomes.

EDX Medical Group to launch highly accurate early detection test for testicular cancer

EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care.

EDX Medical Group raises £3.0 million to accelerate its prostate cancer ‘super test’

EDX Medical Group plc has secured £3 million by issuing 21.4 million new shares at 14p each, boosting its innovative prostate cancer diagnostic efforts.

Search

Search